Feature | March 24, 2011| Keith G. Boman, M.D., FACC

Sudden Cardiac Arrest in Patient With Moderate LV Dysfunction and Positive MTWA Test

Figure 1: Positive MTWA test result

Figure 2: Patients ICD electrocardiogram

During a sudden cardiac arrest (SCA), heart function ceases – abruptly and without warning – most often due to the onset of a ventricular tachyarrhythmia [1]. Because out-of-hospital survival is less than 8 percent, prediction and prevention are critically important [2]. Microvolt T-wave alternans (MTWA), a subtle alternating pattern in T-wave morphology on the surface electrocardiogram is a marker of arrhythmic vulnerability and SCA risk [3, 4], demonstrating prognostic value in various patient populations including those with ischemic and non-ischemic cardiomyopathy [5-7]. We report a case of a patient who experienced SCA one year after a positive MTWA test.

Case History
An asymptomatic 64-year-old male had a history of coronary artery disease and coronary bypass surgery in 1992. A computed tomography (CT) angiogram performed in September 2006 revealed subtotal occlusion of the right coronary artery; however, angioplasty could not be completed due to anatomical complexity. An echocardiogram showed a left ventricular ejection fraction (LVEF) of 45-50 percent and significant left ventricular hypertrophy secondary to moderate aortic stenosis. Given his clinical profile, an MTWA test was ordered to further clarify his risk of ventricular arrhythmias and SCA.

MTWA Study and Follow-up
In October 2009, MTWA testing was performed with treadmill exercise using the Analytic Spectral Method to measure alternans (HearTwave II, Cambridge Heart, Tewksbury, Mass.). At the time of the test, the patient was in normal sinus rhythm with intermittent ventricular ectopy. The MTWA result was positive with sustained alternans present in several leads with an onset heart rate of 106 bpm (Fig. 1). The positive MTWA study along with the patient’s other risk factors prompted an evaluation by an electrophysiologist.

An electrophysiology study (EPS) was performed resulting in inducible ventricular tachycardia with two extrastimuli, and a dual-chamber implantable cardioverter defibrillator (ICD) (Secura DR, Medtronic, Minneapolis, Minn.) was implanted in November 2009. One year later while resting at home, the patient reported feeling a “flutter” in his heart followed by a shock from the device. Review of the ICD electrogram (Fig. 2) confirmed that the patient experienced an episode of ventricular fibrillation which was successfully terminated by a 23.7 J defibrillation shock on Dec. 2, 2010.

Discussion
Reduced left ventricular ejection fraction is an established risk factor for cardiac arrest and is currently the primary determinant of ICD eligibility; however, EF lacks sensitivity [8] due to the fact that the majority of SCA deaths occur in patients with an EF more than 30-35 percent [9, 10]. This patient did not have significant LV dysfunction, but had several other clinical factors associated with increased risk of SCA including ischemic cardiomyopathy [11], left ventricular hypertrophy [12] and aortic stenosis [13].

MTWA has been cited as a useful adjunct tool in such patients with moderate to preserved LVEF for whom SCA is a “real but difficult-to-ascertain risk” [14]. MTWA can help guide SCA risk management strategies which may include treatment of underlying ischemia, medical optimization, tighter glucose control, lifestyle changes – or, when appropriate, EPS referral and possible EPS or ICD implantation.

“Per current primary prevention guidelines, this patient would not have received life-saving ICD therapy if he had not undergone an MTWA study,” noted Keith Boman, M.D., the patient’s cardiologist. “MTWA is a tool to help clarify the overall arrhythmic risk, particularly for patients who have known risk factors but who fall into this ‘gray area’ in terms of ICD eligibility.”

References
1. Bayes de Luna A, Coumel P, and Leclercq JF. "Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases." Am Heart J, 1989; 117(1): 151-9.
2. Lloyd-Jones D, Adams RJ, Brown TM, et al. "Heart disease and stroke statistics--2010 update: a report from the American Heart Association." Circulation; 121(7): e46-e215.
3. Pastore JM, Girouard SD, Laurita KR, Akar FG, and Rosenbaum DS. "Mechanism linking T-wave alternans to the genesis of cardiac fibrillation." Circulation, 1999; 99(10): 1385-94.
4. Rosenbaum DS, Jackson LE, Smith JM, Garan H, Ruskin JN, and Cohen RJ. "Electrical Alternans and Vulnerability to Ventricular Arrhythmias." N Engl J Med, 1994; 330(4): 235-241.
5. Chow T, Kereiakes DJ, Bartone C, et al. "Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy." J Am Coll Cardiol, 2006; 47(9): 1820-7.
6. Salerno-Uriarte JA, De Ferrari GM, Klersy C, et al. Prognostic Value of T-Wave Alternans in Patients With Heart Failure Due to Nonischemic Cardiomyopathy: Results of the ALPHA Study. J Am Coll Cardiol 2007; 50(19): 1896-1904.
7. Bloomfield DM, Bigger JT, Steinman RC, et al. "Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction." J Am Coll Cardiol, 2006; 47(2): 456-63.
8. Buxton AE, Lee KL, Hafley GE, et al. "Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study." J Am Coll Cardiol, 2007; 50(12): 1150-7.
9. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. "Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival." J Am Coll Cardiol, 1997; 30(6): 1500-5.
10. Stecker EC, Vickers C, Waltz J, et al. "Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study." J Am Coll Cardiol, 2006; 47(6): 1161-6.
11. Huikuri HV, Castellanos A, and Myerburg RJ. "Sudden death due to cardiac arrhythmias." N Engl J Med, 2001; 345(20): 1473-82.
12. Haider AW, Larson MG, Benjamin EJ, and Levy D. "Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death." J Am Coll Cardiol, 1998; 32(5): 1454-9.
13. Kulbertus HE. "Ventricular arrhythmias, syncope and sudden death in aortic stenosis." European Heart Journal 1988; 9(suppl E): 51-52.
14. Mirro MJ. "Strategies for reducing sudden cardiac death: Application of microvolt T-wave alternans testing in clinical practice." Heart Rhythm, 2009; 6(3): S45-S48.

This case study was supplied by Cambridge Heart

For more information: www.cambridgeheart.com

Related Content

atrial fibrillation, stroke risk, aspirin vs blood thinners, JACC study
News | Antiplatelet and Anticoagulation Therapies| June 24, 2016
More than 1 in 3 atrial fibrillation (AF) patients at intermediate to high risk for stroke are treated with aspirin...
Biotronik, CardioStim 2016 Innovation Award, MRI AutoDetect, Ilivia ICDs
News | EP Lab| June 23, 2016
Biotronik announced it was the winner of the Cardiostim Innovation Award in the category “Best Practice Improvement”...
Zoll LifeVest wearable defibrillator, WEARIT-II Registry results, CardioStim EuroPace 2016
News | Defibrillator Monitors| June 21, 2016
Zoll Medical Corp. announced that patients experience a high one-year survival rate following use of the LifeVest...
News | Implantable Cardioverter Defibrillators (ICD)| June 14, 2016
Medtronic plc announced results from several feasibility studies evaluating a new approach to implantable cardioverter...
Medtronic, Micra TPS pacemaker, Global Clinical Trial, Cardiostim 2016
News | Pacemakers| June 09, 2016
Medtronic plc announced new results from the Medtronic Micra Transcatheter Pacing System (TPS) Global Clinical Trial in...
EPIC Alliance, women in electrophysiology, cardiac rhythm management, Cardiostim 2016 conference
News | EP Lab| June 08, 2016
Physicians presented original research and real-world clinical evidence at a symposium organized by the...
Medtronic, Micra TPS, transcatheter pacing system, pacemaker, Jersey Shore University Medical Center, New Jersey first
News | Pacemakers| June 06, 2016
Jersey Shore University Medical Center, part of Meridian CardioVascular Network, is the first hospital in New Jersey to...
female patients, atrial fibrillation, blood thinning therapy, AFDST, decision support tool, Cincinnati
News | Antiplatelet and Anticoagulation Therapies| June 02, 2016
Female atrial fibrillation patients are less likely than their male counterparts to receive blood thinning therapies to...
Biotronik, CardioMessenger Smart, remote monitoring, ICD, pacemaker
Technology | EP Device Monitoring Systems| June 01, 2016
Biotronik announced the launch of CardioMessenger Smart in the United States. CardioMessenger Smart is a portable...
Corsens Cardiac Monitor, FDA 510k pre-market notification
News | Patient Monitors| May 26, 2016
Corsens Medical Ltd. announced it has successfully completed filing of a Pre-Marketing Notification (510(k)) with the U...
Overlay Init